HALEOSLABS1,450.00

HALEOS LABS LIMITED

· Pharma & Health
₹ CrorePeersALBERTDAVDVALIANTLABMEDICOMEDICAMEQZIMLABAAREYDRUGSNECLIFEANUHPHRMcap ₹438 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)197.36164.10198.62198.62
Receivable Days (DSO)61.2672.8367.0767.07
Payable Days (DPO)143.69129.70152.79139.59
Cash Conversion Cycle (days)114.93107.23112.90126.10
Working Capital Turnover28.5640.5348.8947.49
Asset Turnover0.780.880.730.73
Cash Conversion (CFO/Net Income)3.841.822.092.09
CFO/EBITDA0.780.760.830.83
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.